NCT00201786View on ClinicalTrials.gov

Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

October 31, 2007

Study Completion Date

July 31, 2013

Conditions
Graft-Versus-Host Disease
Interventions
DRUG

Pentostatin

Pentostatin is given at a dose of 1.5 mg/m2/day IV x 3 consecutive days. Each IV infusion of pentostatin will be administered over 20-30 minutes in 100-250 ml of D5W or NS. To prevent nephrotoxicity, patients will also receive 500 ml normal saline as pre- and post drug hydration (total 1000 ml).

Trial Locations (1)

43210

Ohio State University, Columbus

All Listed Sponsors
lead

Ohio State University Comprehensive Cancer Center

OTHER

NCT00201786 - Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease | Biotech Hunter | Biotech Hunter